Immutep targets $100m for lung cancer drug trial tests
Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CRG | Ann:Placement of new shares (Price Sensitive) | 31/05/24 | 0 | 60 | |||
|
|||||||
CRG | Ann:Notice under section 708A(5)(e) of Corps Act 2001 (Price Sensitive) | 31/05/24 | 0 | 50 | |||
|
|||||||
CRG | Ann:Quotation of Additional Securities (Price Sensitive) | 21/05/24 | 0 | 111 | |||
|
|||||||
CRG | Ann:Disclosure under section 708A(5)(e) of Corpos Act 2001 (Price Sensitive) | 21/05/24 | 0 | 114 | |||
|
|||||||
CRG | Ann:Placement of new Shares (Price Sensitive) | 30/04/24 | 0 | 146 | |||
|
|||||||
CRG | Ann:Notice under Section 708A(5)(e) of Corps Act 2001 (Price Sensitive) | 30/04/24 | 0 | 154 | |||
|
|||||||
CRG | Ann:Final Notice of Directors Interests - Steer | 10/04/24 | 0 | 147 | |||
|
|||||||
CRG | Ann:NSX Directors Undertaking: Brown (Price Sensitive) | 10/04/24 | 0 | 176 | |||
|
See All Discussions